1. Hepatitis B immune globulin
Drugbank ID : DB05276

2. Description :
Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. According to the Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first anti-cancer vaccine. HBIG is prepared from the plasma of donors who have high antibody levels of the hepatitis B surface antigen. It is extracted from the Cohn fraction II. During the process, viruses are deactivated, and in the final steps, solvents used in the preparation are removed. The preparation is tested for absence of HIV, HCV, herpes virus, and reovirus.

3. Indication : Pharmacodynamics : NA
Investigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications.
Pharmacodynamics : NA

4. Mechanism of action :
In countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer.

5. Targets : Affected organisms : Categories : HBsAg
Humans and other mammals
Categories : NA

6. Brands : Hepagam B
Company : Cangene Bio Pharma Inc.
Description : HepaGam B, Hepatitis B Immune Globulin Intravenous (Human), is a solvent/detergent- treated sterile solution of purified gamma globulin containing anti-HBs. It is prepared from plasma donated by healthy, screened donors with high titers of anti-HBs that is purified by an anion- exchange column chromatography manufacturing method9,10. HepaGam B (hepatitis b immune globulin human) is formulated as a 5% (50 mg/mL) protein solution with 10% maltose and 0.03% polysorbate 80 at pH 5.6. It is available in 1 mL and 5 mL single dose vials. The product appears as a clear to opalescent liquid.
Used for/Prescribed for : HepaGam B™, Hepatitis B Immune Globulin Intravenous (Human), is indicated for the prevention of hepatitis B recurrence following liver transplantation, in HBsAg-positive liver transplant patients. Formulation : 50 mg/mL; 312 [iU]/mL; 220 [iU]/mL
Form : injection, solution
Route of administration : intramuscular

7. NA

8. Brands : Nabi-HB
Company : Biotest Pharmaceuticals Corporation
Description : Nabi-HB (hepatitis b vaccine recombinant) , is a sterile solution of immunoglobulin (5 ± 1% protein) containing antibodies to hepatitis B surface antigen (anti-HBs). It is prepared from plasma donated by individuals with high titers of anti-HBs.
Used for/Prescribed for : Nabi-HB, Hepatitis B Immune Globulin (Human), is indicated for treatment of acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute HBV infection in the following settings: Acute Exposure to Blood Containing HBsAg; Perinatal Exposure of Infants Born to HBsAg-positive Mothers; Sexual Exposure to HBsAg-positive Persons; Household Exposure to Persons with Acute HBV Infection.
Formulation : 1560 [iU]/5mL; 312 [iU]/mL
Form : Injection
Route of administration : intramuscular

9. NA

10. References :